Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
KSQ Therapeutics received early financing of $76.0M on 2017-10-02.
| Series | Round size | Date |
|---|---|---|
| Series B | $76M | 10/2017 |
| Series C | $80M | 09/2018 |
| Investors | Security type |
|---|---|
| Polaris Partners | Series B |
| ARCH Venture Partners | Series B |
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | Series B |
| Flagship Pioneering Inc | Series B |
| Polaris Partners | Series C |
| Lilly Asia Ventures | Series C |
| Invus | Series C |
| Baillie Gifford | Series C |
| ARCH Venture Partners | Series C |
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | Series C |
| Flagship Pioneering Inc | Series C |
| Cowen Healthcare Investments | Series C |
KSQ Therapeutics's top competitor, Blueprint Medicines, earned an annual revenue of $508.8M.
KSQ Therapeutics's smallest competitor is CRISPR Therapeutics with revenue of $37.3M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Blueprint Medicines | $84,447 | $508.8M | 495 | 11 |
| Ardelyx | $46,078 | $333.6M | 86 | 86 |
| Rigel Pharmaceuticals | $83,403 | $179.3M | 158 | 6 |
| CRISPR Therapeutics | $82,541 | $37.3M | 304 | 23 |
| Epizyme | $86,952 | $37.4M | 124 | - |
| Ophthotech | $46,140 | $210.0M | 58 | - |
| XenoPort, Inc. | - | $41.2M | 200 | - |
Zippia gives an in-depth look into the details of KSQ Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about KSQ Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at KSQ Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by KSQ Therapeutics. The data presented on this page does not represent the view of KSQ Therapeutics and its employees or that of Zippia.
KSQ Therapeutics may also be known as or be related to KSQ Therapeutics, KSQ Therapeutics Inc, KSQ Therapeutics, Inc. and Ksq Therapeutics, Inc.